YouSen Health Completes Over RMB 200 Million Series A Financing to Advance Oncology and Autoimmune Innovative Drug Pipeline

Shanghai Jiaochen Biomedical Co., Ltd. (hereinafter referred to as “Jiaochen Biomedical”) recently announced the completion of its Series A financing round, raising over RMB 200 million. The round was led by Shenzhen Fenxiang Investment, with participation from Zhangjiang Haoheng and Yingke Capital, while existing shareholders continued their investment. The funds raised will be used to conduct and accelerate domestic and international clinical trials for UA007 and UA021, advance the research and development of small-molecule drugs targeting multiple novel targets, and support the development of specific bispecific antibodies.

Huang Fanzhi, Co-Founder and Managing Partner of the Healthcare Fund at Lead Investor, stated, “It is an honor to participate in Jiaochen Biomedical’s Series A financing. Jiaochen Biomedical has established a relatively comprehensive R&D team with complementary expertise and resources, focusing on next-generation oncology and autoimmune diseases, which presents broad market prospects. The project progresses in a phased manner, with differentiated indications and sustainable R&D capabilities. We look forward to Jiaochen Biomedical’s continued rapid development in the future.”

Wang Wenjie, Deputy General Manager of Zhangjiang Haoheng, stated: “The team at Jiaochen Biomedical possesses many years of experience in new drug research and development both domestically and internationally. It has established a presence across both large-molecule and small-molecule pipelines targeting specific disease spectra, creating a differentiated portfolio of products under development with global market positioning. The Zhangjiang Suifeng Fund, managed by Zhangjiang Haoheng, is a science and technology innovation sub-fund under the Pudong Science and Technology Innovation Fund of Funds, with Zhangjiang High-Tech serving as the cornerstone investor. It will fully support Jiaochen Biomedical’s entrepreneurship and development within Zhangjiang Science City.”

Dr. Li Jinsong, Dr. Hu Tao, and Dr. Peng Shengbin, the three co-founders of Shanghai Jiaochen Biomedical Co., Ltd., expressed their gratitude to investors for their recognition and support of the company’s team and pipeline. Chairman Li Jinsong stated, “We thank our investors for their endorsement of our corporate philosophy and team. Shanghai Jiaochen Biomedical aims to become a leading innovative drug R&D company. In the future, the company will focus on establishing an efficient translational medicine R&D system by optimizing its international market presence, organizational structure, cost management, and operational efficiency, with the goal of developing cost-controllable innovative drugs targeting major global therapeutic markets.”

Shanghai Jiaochen Biomedical Co., Ltd. is an innovative pharmaceutical company dedicated to the research and development of first-in-class and best-in-class drugs, focusing on cancer and autoimmune diseases. The company targets undruggable targets and key oncogenes, with a pipeline that includes small-molecule targeted therapies, recombinant proteins, and monoclonal/bispecific antibody drugs. The core management team comprises former executives from multinational pharmaceutical companies and leading domestic CROs, bringing extensive experience in innovative drug development. Currently, the company’s UA007 project is conducting one Phase II clinical trial in China for the prevention and treatment of CID, as well as one Phase I clinical trial for the treatment of acute gout. The small-molecule targeted therapy UA021 for autoimmune diseases is in the IND-enabling stage and is expected to initiate global clinical trials in 2022.

FenXiang Investment was established in Shenzhen in 2007. It has invested in over 200 companies and currently manages assets exceeding RMB 8 billion. Since 2010, FenXiang Investment has strategically positioned itself in the healthcare sector, focusing on precision medicine. Aligning with global R&D standards and adapting to the demands of China’s emerging market, it concentrates on four key areas: biotechnology, new drug development, innovative medical services, and cutting-edge medical devices. The firm currently manages four healthcare-themed funds and boasts an independent professional medical investment team of 12 members with extensive investment experience and strong professional backgrounds. To date, it has invested in more than 80 healthcare projects, with the total size of its healthcare funds nearing RMB 4.5 billion. Key investment portfolio companies include BGI Genomics (300676.SZ), Meinian Onehealth (002044.SZ), Buchang Pharma (603858.SH), Zeltis Pharma (688266.SH), Genetron Health (GTH.US), Tiansheng Medical (688013.SH), Medprin Regenerative Medical Technologies (301033.SZ), Haiyou New Materials (688680.SH), Vazyme Biotech (688105.SH), ACROBiosystems (301080.SZ), iCarbonX, Tongxin Medical, Fapon Biotechnologies, Huajin Pharmaceutical, Haichang Pharmaceutical, Gosen Pharmaceutical, Orange Dental, Aokeda, and BinHui Bio.

Zhangjiang Haoheng is an equity investment management company initiated and established by Zhangjiang High-Tech in 2019. With a first-phase fund size of RMB 2 billion, it focuses on technological innovation enterprises in fields such as integrated circuits, biopharmaceuticals and medical devices, next-generation information technology, and intelligent manufacturing. Rooted in the core industries of Zhangjiang Science City, the company concentrates on “hard tech” sectors and industries, leveraging capital to empower technological innovation. Meanwhile, by drawing on Zhangjiang High-Tech’s rich industrial ecosystem and tapping into diverse innovation elements and resources, it provides enterprises with a variety of support and services, including space solutions, talent acquisition, and policy assistance.

In just ten years, Yingke Capital has risen to become one of China’s top investment firms, with assets under management exceeding RMB 50 billion. Ninety percent of the funds under its stewardship come from financial institutions and state-owned enterprises. Guided by its mission to “unlock the forces driving economic progress,” the firm focuses on technology-driven innovators that align with national development strategies and possess key core technologies. It concentrates on core sectors such as biopharmaceuticals and hard tech, adhering to a dual strategy of “biopharmaceutical industry investment + life sciences industrial holdings.” By precisely positioning itself across more than 100 leading companies spanning the entire biopharmaceutical value chain, Yingke Capital is recognized as a gateway, platform-style investment institution for capital entering the biopharmaceutical sector.